GIA
LTRN icon

GHP Investment Advisors’s Lantern Pharma LTRN Stock Holding History

GHP Investment Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300
Closed -$2K – 942
2022
Q2 		$2K Buy
+300
New +$1.79K ﹤0.01% 852

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GHP Investment Advisors's LTRN Position: Q3 2022 in Review

GHP Investment Advisors sold out of Lantern Pharma (LTRN) in Q3 2022, closing a stake of 300 shares — an estimated $2K sold.

GHP Investment Advisors first reported a position in LTRN in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 26 funds tracked by Wall St. Rank hold LTRN as of Q3 2022.

  • GHP Investment Advisors reported no remaining Lantern Pharma position as of Q3 2022 after selling out during the quarter.
  • GHP Investment Advisors sold 300 Lantern Pharma shares in Q3 2022, an estimated $2K.
  • GHP Investment Advisors first reported a position in Lantern Pharma in Q2 2022 and held it in 1 quarter.
  • GHP Investment Advisors's Lantern Pharma position peaked at $2K in Q2 2022.
  • 26 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2022.

Based on GHP Investment Advisors's 13F filing for Q3 2022, filed 28 Oct 2022.